Jaktinib

Jaktinib
Legal status
Legal status	Investigational;
Identifiers
CAS Number	1619927-66-0;
DrugBank	DB17545;
Chemical and physical data
Formula	C23H22N6O2
Molar mass	414.469 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N(C=1N=C(C2=CC=C(C(NCC#N)=O)C=C2)C=CN1)C3=CC=C(C=C3)N4C(COCC4([2H])[2H])([2H])[2H];
	InChI InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)/i13D2,14D2; Key:ZVHNDZWQTBEVRY-RYIWKTDQSA-N;

Jaktinib is a janus kinase inhibitor under development for myelofibrosis.^[1]^[2] It is a deuterated-drug analog of momelotinib.^[1]

References

^ ^a ^b Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Wu, Liqing; Yu, Wenjuan; Jin, Jie (December 2022). "Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial". American Journal of Hematology. 97 (12): 1510–1519. doi:10.1002/ajh.26709. ISSN 1096-8652. PMC 10092883.1510-1519&rft.date=2022-12&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092883#id-name=PMC&rft.issn=1096-8652&rft_id=info:doi/10.1002/ajh.26709&rft.aulast=Zhang&rft.aufirst=Yi&rft.au=Zhou, Hu&rft.au=Jiang, Zhongxing&rft.au=Wu, Dengshu&rft.au=Zhuang, Junling&rft.au=Li, Wei&rft.au=Jiang, Qian&rft.au=Wang, Xiuli&rft.au=Huang, Jinwen&rft.au=Zhu, Huanling&rft.au=Yang, Linhua&rft.au=Du, Xin&rft.au=Li, Fei&rft.au=Xia, Ruixiang&rft.au=Zhang, Feng&rft.au=Hu, Jianda&rft.au=Li, Yan&rft.au=Hu, Yu&rft.au=Liu, Jing&rft.au=Jin, Chenghao&rft.au=Sun, Kai&rft.au=Zhou, Zeping&rft.au=Wu, Liqing&rft.au=Yu, Wenjuan&rft.au=Jin, Jie&rft_id=https://pubmed.ncbi.nlm.nih.gov/36054786/&rfr_id=info:sid/en.wikipedia.org:Jaktinib" class="Z3988">
^ Zhang, Yi; Zhou, Hu; Xiao, Zhi-Jian; Duan, Minghui; Gao, Sujun; He, Guangsheng; Jing, Hongmei; Li, Junmin; Ma, Liangming; Zhu, Huanling; Chang, Chunkang; Du, Xin; Hong, Mei; Li, Xin; Liu, Qingchi; Wang, Wei; Xu, Na; Yang, Haiping; Zhao, Qingwei; Jin, Jie (2023). "Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study". Journal of Clinical Oncology. 41 (16_suppl): 7061–7061. doi:10.1200/JCO.2023.41.16_suppl.7061.7061-7061&rft.date=2023&rft_id=info:doi/10.1200/JCO.2023.41.16_suppl.7061&rft.aulast=Zhang&rft.aufirst=Yi&rft.au=Zhou, Hu&rft.au=Xiao, Zhi-Jian&rft.au=Duan, Minghui&rft.au=Gao, Sujun&rft.au=He, Guangsheng&rft.au=Jing, Hongmei&rft.au=Li, Junmin&rft.au=Ma, Liangming&rft.au=Zhu, Huanling&rft.au=Chang, Chunkang&rft.au=Du, Xin&rft.au=Hong, Mei&rft.au=Li, Xin&rft.au=Liu, Qingchi&rft.au=Wang, Wei&rft.au=Xu, Na&rft.au=Yang, Haiping&rft.au=Zhao, Qingwei&rft.au=Jin, Jie&rfr_id=info:sid/en.wikipedia.org:Jaktinib" class="Z3988">

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[AJHemat2022-1] Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Wu, Liqing; Yu, Wenjuan; Jin, Jie (December 2022). "Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial". American Journal of Hematology. 97 (12): 1510–1519. doi:10.1002/ajh.26709. ISSN 1096-8652. PMC 10092883.1510-1519&rft.date=2022-12&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092883#id-name=PMC&rft.issn=1096-8652&rft_id=info:doi/10.1002/ajh.26709&rft.aulast=Zhang&rft.aufirst=Yi&rft.au=Zhou, Hu&rft.au=Jiang, Zhongxing&rft.au=Wu, Dengshu&rft.au=Zhuang, Junling&rft.au=Li, Wei&rft.au=Jiang, Qian&rft.au=Wang, Xiuli&rft.au=Huang, Jinwen&rft.au=Zhu, Huanling&rft.au=Yang, Linhua&rft.au=Du, Xin&rft.au=Li, Fei&rft.au=Xia, Ruixiang&rft.au=Zhang, Feng&rft.au=Hu, Jianda&rft.au=Li, Yan&rft.au=Hu, Yu&rft.au=Liu, Jing&rft.au=Jin, Chenghao&rft.au=Sun, Kai&rft.au=Zhou, Zeping&rft.au=Wu, Liqing&rft.au=Yu, Wenjuan&rft.au=Jin, Jie&rft_id=https://pubmed.ncbi.nlm.nih.gov/36054786/&rfr_id=info:sid/en.wikipedia.org:Jaktinib" class="Z3988">

[2] Zhang, Yi; Zhou, Hu; Xiao, Zhi-Jian; Duan, Minghui; Gao, Sujun; He, Guangsheng; Jing, Hongmei; Li, Junmin; Ma, Liangming; Zhu, Huanling; Chang, Chunkang; Du, Xin; Hong, Mei; Li, Xin; Liu, Qingchi; Wang, Wei; Xu, Na; Yang, Haiping; Zhao, Qingwei; Jin, Jie (2023). "Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study". Journal of Clinical Oncology. 41 (16_suppl): 7061–7061. doi:10.1200/JCO.2023.41.16_suppl.7061.7061-7061&rft.date=2023&rft_id=info:doi/10.1200/JCO.2023.41.16_suppl.7061&rft.aulast=Zhang&rft.aufirst=Yi&rft.au=Zhou, Hu&rft.au=Xiao, Zhi-Jian&rft.au=Duan, Minghui&rft.au=Gao, Sujun&rft.au=He, Guangsheng&rft.au=Jing, Hongmei&rft.au=Li, Junmin&rft.au=Ma, Liangming&rft.au=Zhu, Huanling&rft.au=Chang, Chunkang&rft.au=Du, Xin&rft.au=Hong, Mei&rft.au=Li, Xin&rft.au=Liu, Qingchi&rft.au=Wang, Wei&rft.au=Xu, Na&rft.au=Yang, Haiping&rft.au=Zhao, Qingwei&rft.au=Jin, Jie&rfr_id=info:sid/en.wikipedia.org:Jaktinib" class="Z3988">

[1]

[2]